The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×2•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

Telix and Regeneron Partner to Develop Advanced Prostate Cancer Therapies

Key Facts

1Telix Pharmaceuticals will evaluate its radiopharmaceutical TLX-591 in combination with Regeneron’s Libtayo.

2The collaboration focuses on treating advanced prostate cancer patients.

4 months ago

Version History

Version 24 months ago

What changed: Updated the story to include strong Q1 2026 financial results and the reaffirmation of full-year revenue guidance that exceeded market consensus.

Version 14 months ago

What changed: The story was updated to include the appointment of two new Non-Executive Directors to Telix's board as part of its expansion and succession planning.

Telix Pharmaceuticals has entered into a strategic collaboration with Regeneron to evaluate a combination therapy for advanced prostate cancer, pairing its radiopharmaceutical TLX-591 with Regeneron’s Libtayo. Alongside this clinical expansion, the company reported strong Q1 2026 financial results, with revenue reaching $230M, a 24% increase year-over-year. Telix also reaffirmed its FY26 revenue guidance of $950–$970M, surpassing market consensus expectations. To support this growth, the company is strengthening its governance with the appointment of two new Non-Executive Directors effective May 2026. The stock is currently trading at a forward EV/sales multiple of 3.6x, with analysts expecting a rapid earnings inflection driven by its successful imaging franchise, including Illuccix. This dual momentum in clinical innovation and financial performance underscores Telix's robust trajectory in the oncology sector.